Using B7-H3 CAR T cells after radiation to treat a deadly brain tumor in children and young adults
B7-H3 CAR T cells following initial radiation for children and young adults with diffuse intrinsic pontine glioma
This study is testing a new treatment using special immune cells called B7-H3 CAR T cells for children and young adults with a tough brain tumor called DIPG, hoping to help them live longer after their initial radiation therapy.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Seattle Children's Hospital NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11048809 on NIH RePORTER |
What this research studies
This research investigates the use of B7-H3 CAR T cells in children and young adults diagnosed with diffuse intrinsic pontine glioma (DIPG), a highly aggressive brain tumor. The approach involves administering these engineered immune cells after the patients have received initial radiation therapy, aiming to improve survival rates. The study builds on previous findings that showed promising results in a first-in-human trial, where patients treated with CAR T cells had a longer median overall survival compared to historical data. Patients will be monitored closely, and advanced imaging techniques will be used to assess treatment efficacy and identify biomarkers.
Who could benefit from this research
Good fit: Ideal candidates for this research are children and young adults diagnosed with diffuse intrinsic pontine glioma who have undergone initial radiation therapy.
Not a fit: Patients with other types of brain tumors or those who have not received initial radiation therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly extend survival and improve the quality of life for children and young adults with DIPG.
How similar studies have performed: Previous studies using CAR T cell therapy have shown promising results in other cancers, indicating potential for success in this novel application for DIPG.
Where this research is happening
Seattle, United States
- Seattle Children's Hospital — Seattle, United States (Active)
Researchers
- Principal investigator: Vitanza, Nicholas a — Seattle Children's Hospital
- Study coordinator: Vitanza, Nicholas a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.